AUG 10, 2026 · PHASE 1/2 TRIAL
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
ClinicalTrials.gov
This is a Phase 1/2 first-in-human trial registration with no results posted; it describes planned safety, tolerability, and dose-finding work in a new CDK4 inhibitor.
Reported
Estimated enrollment380
Study phasePhase 1, Phase 2
Primary outcome measure (Phase 1)Occurrence of Dose Limiting Toxicities (DLT…